Cargando…

PB2122: THE EFFICACY OF THE STANDARD AND INTENSIVE CHEMOTHERAPY IN ELDERLY PATIENTS WITH DOUBLE- AND TRIPLE-EXPRESSOR LYMPHOMA.

Detalles Bibliográficos
Autores principales:	Fujita, M., Itamura, H., miyazaki, M., Ishii, K., Sugihara, A., Sano, H., Okamoto, S., yoshimura, M., Katsuya, H., Ureshino, H., Ando, T., Kimura, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431721/ http://dx.doi.org/10.1097/01.HS9.0000851320.93038.b4

Ejemplares similares

Type II Cryoglobulinemic Membranoproliferative Glomerulonephritis Caused by Mucosa-associated Lymphoid Tissue Lymphoma
por: Sugihara, Ayano, et al.
Publicado: (2023)

Triple Expressor Lymphoma: Presentation With Acute Paraparesis Due to Spinal Cord Compression
por: Alburqueque-Melgarejo, Joseph, et al.
Publicado: (2022)

PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Double or triple-expressor lymphomas: prognostic impact of immunohistochemistry in patients with diffuse large B-cell lymphoma
por: Peña, Camila, et al.
Publicado: (2020)

PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

PB2151: EVALUATION OF BONE MINERAL DENSITY IN LYMPHOMA PATIENTS WITH USING PET/CT AND THE ROLE OF BCL-2
por: Okan, V., et al.
Publicado: (2022)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

PX-2122 pit.
por: Jean-Luc Caron
Publicado: (1999)

PX-2122 pit.
por: Jean-Luc Caron
Publicado: (1999)

PX-2122 pit.
por: Jean-Luc Caron
Publicado: (1999)

PX-2122 pit.
por: Jean-Luc Caron
Publicado: (1999)

PX-2122 pit.
por: Jean-Luc Caron
Publicado: (1999)

PX-2122 pit.
por: Jean-Luc Caron
Publicado: (1999)

PX-2122 pit.
por: Jean-Luc Caron
Publicado: (1999)

PB2076: PEDIATRIC-TYPE FOLLICULAR LYMPHOMA - A NEW PARADIGM IN DIAGNOSIS?
por: Fonseca, L., et al.
Publicado: (2022)

PB2094: PRIMARY MEDIASTINAL B-CELL LYMPHOMA: EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Charfi, M., et al.
Publicado: (2022)

PB2157: TREATMENT WITH DIPHENYLENEIODONIUM CHLORIDE EXHIBITS CELL GROWTH INHIBITORY EFFECTS ON AGGRESSIVE LYMPHOMA CELLS
por: Haingartner, S., et al.
Publicado: (2022)

PB2172: IRON OXIDE NANOPARTICLES INHIBIT DIFFUSE LARGE B LYMPHOMA CELL SURVIVAL AND INVASION
por: Yan-Li, L., et al.
Publicado: (2022)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2092: PRIMARY BONE DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE
por: Abichou, G., et al.
Publicado: (2022)

PB2255: ASSESSMENT OF CHEMOTHERAPY-INDUCED TOXICITY IN CHILDREN WITH HODGKIN LYMPHOMA RECEIVING THE EURONET PROTOCOL
por: Bekhit, Hala, et al.
Publicado: (2023)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

PB2129: COULD LYMPHOPENIA PREDICT OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA?
por: Merchan Muñoz, B., et al.
Publicado: (2022)

PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER
por: Kammoun, F., et al.
Publicado: (2022)

PB2062: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN’S LYMPHOMA.
por: Ben Sghaier, R., et al.
Publicado: (2022)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2071: INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA
por: Callejas Charavia, M., et al.
Publicado: (2022)

PB2131: CLINICAL CHARACTERISTICS AND TREATMENTS OUTCOMES OF PRIMARY GASTROINTESTINAL LYMPHOMA:RETROSPECTIVE SINGLE CENTER STUDY FROM MOROCCO
por: Nora, E., et al.
Publicado: (2022)

PB2078: A RETROSPECTIVE ANALYSIS OF THE EFFICACY OF LOW-DOSE METRONOMIC CYCLOPHOSPHAMIDE FOR TREATMENT IN PATIENTS WITH LOW GRADE NON-HODGKIN LYMPHOMA
por: Han, B., et al.
Publicado: (2022)

PB2120: HIV AND MALIGNANT HEMOPATHIES
por: Khibri, H., et al.
Publicado: (2022)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2291: EFFICACY OF SPLENECTOMY IN SPLENIC MARGINAL ZONE LYMPHOMA
por: Yevstakhevych, Yuriy, et al.
Publicado: (2023)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

Double-Expressor Appendiceal Burkitt's Lymphoma: A Case Report and Literature Review
por: Dukmak, Osama N., et al.
Publicado: (2022)

Diffuse Large B-cell Lymphoma Involving an Abundant Infiltration of T Follicular Helper Cells
por: Ishii, Keitaro, et al.
Publicado: (2022)

PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY
por: Sehn, L. H., et al.
Publicado: (2022)

PB2090: TREATMENT OUTCOME OF ORBITAL MARGINAL ZONE B CELL LYMPHOMA -- TEN YEARS FOLLOW UP IN A SINGLE INSTITUTION
por: Tan, T.-D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dmttm80p2iqdif5ek59b1a554j